Letter to Optionholders - Notice of Expiry of Listed Options
Released
Released
Announcement PDF
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au
ASX Announcement
29 April 2026
Notification of Expiry of Listed Options
Melbourne, Australia, 29 April 2026: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or
“the Company”) advises that the attached letter will be sent to registered holders of listed options
(ASX:AVEOA) (Listed Options) which are exercisable at $0.012 per Option on or before 5:00pm
(AEST) on Sunday, 10 May 2026.
Holders of Listed Options can exercise all or part of their Listed Options prior to the expiry date by
completing and returning a Notice of Exercise as attached to the letter specifying the number of
options being exercised and by making payment in cleared funds of the total exercise price for the
number of Listed Options being exercised. There is no obligation upon Option holders to exercise
their Options.
The Options will cease trading on the ASX at the close of trade on Monday, 4 May 2026, being
four business days prior to the expiry date (given the expiry date is a Sunday).
For enquiries, please contact
Dr Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
+61 3 9002 5000
This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.
About Avecho
Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health
products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®
). TPM®
is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance
the solubility and oral, dermal and transdermal absorption of drugs and nutrients.
Avecho’s lead asset is a proprietary cannabidiol (“CBD”) TPM soft-gel capsule demonstrated to increase
CBD absorption. The CBD soft-gel capsule is currently undergoing Phase III clinical development for
the treatment of insomnia.
See more here - avecho.com.au
About Insomnia
Insomnia is a sleep disorder defined as dissatisfaction with sleep quantity or quality associated with
difficulty initiating sleep, difficulty maintaining sleep and the inability to return to sleep on awakening.
It can manifest as a primary indication or be symptom of other disorders, including anxiety and
depression. Chronic insomnia is the most prevalent manifestation, characterised by insomnia symptoms
occurring at least three nights per week and for at least three months. Consequences of insomnia
include daytime sleepiness, poor memory function, decline in concentration with negative impacts on
social and work activities. Approximately 10-30% of the global population have symptoms of insomnia,
with 10-15% classified as chronic1
. Based on the current global population, up to 237M people are
affected by insomnia, with the sleep economy and sleep aids market estimated to reach US$950Bn by
1
https://www.thegoodbody.com/insomnia-statistics/
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au
20322
. In Australia, as many as ~60% of the population have at least some symptoms of insomnia
with a total cost to the Australian economy estimated to be A$19.1 billion3
. In August 2023, the
Australian Government issued a statement indicating that sleep health should be considered a national
priority as important as fitness and nutrition4
.
About Avecho’s Phase III Trial Program
The Company is currently conducting a pivotal (Phase III), multi-centre, randomized, double-blind,
placebo-controlled clinical trial evaluating the efficacy and safety of CBD TPM soft-gel capsules in adults
for use in the reduction of insomnia severity. The trial is the largest of its kind testing cannabidiol,
taking place at multiple sites around Australia. Aided by advice from international sleep and regulatory
experts, the trial has been designed to meet the requirements of the Australian Therapeutic Goods
Administration (“TGA”), US Food and Drug Agency and the European Medicines Agency. Trial
Participants will be randomly assigned to one of three groups to receive nightly doses of either 75mg
or 150mg of CBD, or a placebo for eight weeks. Participants will use validated questionnaires and daily
sleep diaries over the course of the study to record the duration and quality of their sleep.
Further information about the study can be found at ClinicalTrials.gov (Study Identifier: NCT05840822).
A successful Phase III trial is Avecho’s final clinical step in support of a submission to the TGA for
pharmaceutical registration of the CBD TPM soft-gel capsule for the management of insomnia. This
opportunity is particularly significant in Australia, where regulatory changes in 2020 allow for over-the-
counter sales of CBD products direct from pharmacy without a prescription, provided they gain
appropriate approvals. Avecho has an opportunity to be the first in this area as no other Phase III CBD
trials in Australia have succeeded. Initial projections estimated the Australian over-the-counter CBD
market would grow to over US$125M per annum5
.
Forward-Looking Statements
Certain statements in this announcement are forward looking statements. Forward-looking statements
can generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”,
“intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward-
looking statements speak only as at the date of this announcement. These statements are based on
current expectations and beliefs and, by their nature, are subject to a number of known and unknown
risks and uncertainties that could cause the actual results, performances and achievements to differ
materially from any expected future results, performance or achievements expressed or implied by such
forward looking statements.
No representation, warranty or assurance (express or implied) is given or made by Avecho that the
forward-looking statements contained in this announcement are accurate, complete, reliable or
adequate or that they will be achieved or prove to be correct. Except for any statutory liability which
cannot be excluded, Avecho and its respective officers, employees and advisers expressly disclaim any
responsibility for the accuracy or completeness of the forward-looking statements and exclude all
liability whatsoever (including negligence) for any direct or indirect loss or damage which may be
suffered by any person as a consequence of any information in this announcement or any error or
omission therefrom.
Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, Avecho
disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking
statements in these materials to reflect any change in expectations in relation to any forward-looking
statements or any change in events, conditions or circumstances on which any statement is based.
2
https://finance.yahoo.com/news/sleep-economy-sleep-aids-market-133100851.html
3
https://www.deloitte.com/au/en/services/economics/analysis/rise-try-to-shine.html
4
https://www.health.gov.au/sites/default/files/2023-08/bedtime-reading-inquiry-into-sleep-health-awareness-
in-australia.pdf
5
Fresh Leaf Analytics, Australian Medicinal Cannabis Market, H1 2021
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au
Nothing in these materials shall under any circumstances create an implication that there has been no
change in the affairs of Avecho since the date of the announcement.
Avecho’s major projects include delivering TPM enhanced injectable, oral and topical products for the
human health market, including the recently announced application of TPM to cannabinoids. The
Company is also developing TPM®
to enhance feed efficiency and health of livestock.
AVE
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030
Samples/000001/000001
*L000001*
SRN/HIN: SRN WITHHELD
ABN 32 056 482 403
AVE
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030
Notice of Expiry of Listed Options
Options exercisable at $0.012 per Option expiring at 5.00pm (AEST) on 10 May 2026
Dear Optionholder(s)
You are reminded that the Options to subscribe for Ordinary Fully Paid Shares in the capital of Avecho Biotechnology Limited registered in your
name expire at 5.00pm (AEST) on 10 May 2026.
These Options are exercisable wholly or in part by the payment of $0.012 for each Option exercised. Payment must be received by 5.00pm
(AEST) on 10 May 2026. For every one Option exercised, the Optionholder will be allotted one Ordinary Fully Paid Share in the capital of
Avecho Biotechnology Limited.
Step 1: Registration Name
Please check the details provided and update your address via
www.investorcentre.com if any of the details are incorrect.
By making your payment you confirm that you agree to all of the terms
and conditions of the Notice of Expiry.
Payments can be remitted directly via EFT to the bank account below:
Please send your completed Notice of Expiry along with payment
confirmation to: accounts@avecho.com.au
Note: Please use your HIN or SRN and holding name as per the
personalised option expiry form as the reference for your payment to
assist us to match your funds against your form.
Step 2: Make Your Payment
• I/We request that you allot me/us the number of Ordinary Fully Paid Shares applied for and I/we agree to accept such
shares subject to the Constitution of the Company; and
• I/We authorise you to register me/us as the holder(s) of the Ordinary Fully Paid Shares to be alloted and place my/our
name on the register.
Avecho Biotechnology Limited Notice of Expiry
Payment must be received by 5.00pm (AEST) on 10 May 2026
By submitting this Notice of Expiry of Listed Options or by making payment by EFT:
For your security keep your SRN/
HIN confidential.
accounts@avecho.com.au
By Email:
Phone:
+61 (0) 3 9002 5000
For all enquiries:
Bank:
Bank Address:
Account Name:
BSB:
Account Number:
National Australia Bank Limited
288 Lygon Street, Carlton VIC 3053
Avecho Biotechnology Limited
083-170
701477258
Samples/000001/000002/i12
*M00000112Q02*
SRN/HIN: SRN WITHHELD
Registration Name & Optionholding Details For your security keep your SRN/
HIN confidential.
Registration Name:
Daytime
Telephone
.
$
Number of Options registered in your name as at 7.00pm (AEST) on
28 April 2026:
Number of Shares to be issued on full exercise basis:
Amount payable on full exercise at A$0.012 per Option:
21,578
21,578
$258.94
Optionholding
Details:
Make Your Payment
Make your payment via EFT using the payment details below.
Please send your completed Notice of Expiry along with payment confirmation to: accounts@avecho.com.au
MR SAM SAMPLE
FLAT 123
123 SAMPLE STREET
THE SAMPLE HILL
SAMPLE ESTATE
SAMPLEVILLE VIC 3030
Contact Details
Payable at $0.012 per Option
exercised:
Number of Options Exercised:
Avecho Biotechnology Limited Notice of Expiry Payment
Notice of Expiry of Listed Options
STEP 1
STEP 2
Contact
Name
Contact Details
Privacy Notice
The personal information you provide on this Notice is collected by Computershare, as registrar for the securities issuer Avecho Biotechnology Limited, for the
purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. In addition, the issuer may
authorise us on their behalf to send you marketing material or include such material in a corporate communication. You may elect not to receive marketing
material by contacting Computershare using the details provided above or emailing privacy@computershare.com.au. We may be required to collect your personal
information under the Corporations Act 2001 (Cth) and ASX Settlement Operating Rules. We may disclose your personal information to our related bodies
corporate and to other individuals or companies who assist us in supplying our services or who perform functions on our behalf, to the issuer for whom we
maintain securities registers or to third parties upon direction by the issuer where related to the issuers administration of your securityholding, or as otherwise
required or authorised by law. Some of these recipients may be located outside Australia, including in the following countries: Canada, India, New Zealand, the
Philippines, the United Kingdom and the United States of America. For further details, including how to access and correct your personal information, and
information on our privacy complaints handling procedure, please contact our Privacy Officer at privacy@computershare.com.au or see our Privacy Policy at
www.computershare.com/au/privacy-policies.
Bank:
Bank Address:
Account Name:
BSB:
Account Number:
National Australia Bank Limited
288 Lygon Street, Carlton VIC 3053
Avecho Biotechnology Limited
083-170
701477258
Share your feedback
Discover